Literature DB >> 3207894

[Natural history and development of bone metastasis. Apropos of 429 cases].

T Conroy1, L Malissard, D Dartois, E Luporsi, J Stines, C Chardot.   

Abstract

The records of 429 patients seen at the Centre Alexis-Vautrin in 1979 and 1980 with bony metastases were retrospectively reviewed to assess their natural history and survival. Breast was the location of primary lesion in 140 patients (32.6%), lung in 95 patients (22.1%) and prostate in 33 patients (7.7%). The primary tumor was of unknown origin in 42 cases (10.9%). The median survival from time of diagnosis was 5 months. Two and 5-year survival rates were 17.5 and 5.1% respectively. According to the nature of the primary tumor, 2 and 5-year survival periods for bony metastases were 36.4 and 7.9% in breast cancer, 33.3 and 15.2% in prostatic cancer, 4.3 and 2.1% in metastases of unknown origin, 2.1 and 0% in pulmonary carcinoma. Multivariate analysis revealed four factors to be of prognostic significance for survival: the nature of the primary tumor, the absence of local relapse, the disease-free interval and the absence of metastases in other sites. Patients with hormone-sensitive lesions or slowly-growing tumors had a better prognosis.

Entities:  

Mesh:

Year:  1988        PMID: 3207894

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  6 in total

1.  Metastatic pancreatic adenocarcinoma presenting as a large pelvic mass mimicking primary osteogenic sarcoma: a series of two patient cases.

Authors:  Nicholas P Webber; Sunil Sharma; Allie H Grossmann; Akram Shaaban; Kevin B Jones; Lester J Layfield; R Lor Randall
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

2.  Surgical treatment of bone metastases in patients with lung cancer.

Authors:  Sandra Utzschneider; Ewa Wicherek; Patrick Weber; Gerwin Schmidt; Volkmar Jansson; Hans Roland Dürr
Journal:  Int Orthop       Date:  2010-06-18       Impact factor: 3.075

Review 3.  [Prognosis-adapted surgical management of bone metastases].

Authors:  S Utzschneider; P Weber; A Fottner; B Wegener; V Jansson; H R Dürr
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

4.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Authors:  Eva Grimaud; Luc Soubigou; Séverine Couillaud; Patrick Coipeau; Anne Moreau; Norbert Passuti; François Gouin; Françoise Redini; Dominique Heymann
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 5.  Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema.

Authors:  Steven de Maat; Kusumam Joseph; Coen Maas; Allen P Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2021-05-06       Impact factor: 8.667

6.  Body aches, tender bones and rapid loss of weight: a case report.

Authors:  Hadda Vijay; Vikram Kishore Navil; Jain Vaibhav; Anita Chopra; Ashish Goel; Rita Sood
Journal:  Cases J       Date:  2009-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.